TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07543757: Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Sponsor: Sequenom, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07543757 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07543757 Rescue Dossier →